Sanofi SA is to expand its vaccine capacity with the acquisition of a privately-owned Austrian company, Origimm Biotechnology GmbH, that has a candidate product for acne vulgaris, a common, chronic skin disease. Acne vulgaris is linked to the bacterium Cutibacterium acnes, a complex Gram positive bacteria. The therapeutic vaccine, which is based on recombinant proteins, entered clinical studies in the third quarter.
